Completed
Combivir, 1592U89, 141W94 Triple Therapy for Antiretroviral-Experienced Patients
What is being tested
Lamivudine/Zidovudine
+ Abacavir sulfate
+ Amprenavir
Drug
Who is being recruted
Treatment Adherence and Compliance+16
+ Blood-Borne Infections
+ Urogenital Diseases
Over 18 Years
+13 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Treatment Adherence and ComplianceBlood-Borne InfectionsUrogenital DiseasesGenital DiseasesBehaviorCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsPatient Acceptance of Health CareRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesVirus DiseasesSexually Transmitted Diseases, ViralHealth BehaviorLentivirus InfectionsPatient ComplianceHIV Infections
Criteria
6 inclusion criteria required to participate
Allowed: AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Antiretroviral therapy with either single or double reverse transcriptase inhibitors.
HIV RNA less than 50,000 copies/ml.
CD4 count greater than 50 cells/mm3.
Show More Criteria
7 exclusion criteria prevent from participating
More than 1 week treatment with any protease inhibitor.
Enrollment in any other investigational drug protocol.
AZT or NNRTIs.
History of clinically relevant pancreatitis or hepatitis within the past 6 months.
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center